Sponsors (6)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced May 20, 2025 by Raul Ruiz · Last progress May 20, 2025
Creates a coordinated package to increase participation of underrepresented groups in clinical trials by funding community outreach and training, setting legal safe harbors for certain trial-related payments and digital tools, allowing manufacturers to pay patient cost‑sharing under strict conditions, and excluding up to $2,000 of trial participation payments from taxable income. The measure directs HHS to award grants for community-based recruitment and training, updates federal anti‑fraud laws to permit common trial supports, establishes safeguards for manufacturer cost‑sharing assistance, and adds a small tax exclusion for participants.
The bill increases access to clinical trials for underrepresented and financially vulnerable Americans by funding outreach, payments, and protections that lower participation barriers, but it also creates fiscal costs, legal and enforcement risks, potential privacy/conflict-of-interest issues, and may lock in a fixed definition that can exclude groups recognized later.
Underrepresented communities (racial/ethnic minorities, people with disabilities, immigrants, tribal communities, non-English speakers, rural residents) will get targeted outreach, multilingual materials, community-site funding, and investigator training that expands local access to and participation in clinical trials.
Clinical trial participants (low-income individuals, rural patients, other underrepresented participants) will face lower out-of-pocket barriers because sponsors can provide payments for travel/meals, supply digital health tools for remote participation, and must promote remuneration to increase inclusion.
Medicare, Medicaid, and other vulnerable beneficiaries can have trial-related out-of-pocket costs covered through sponsor cost-sharing and program safeguards, making trials more financially accessible for beneficiaries.
People who become newly recognized as underrepresented after April 1, 2024 (or groups NIH/FDA later add) could be excluded from the Act's protections and programs because the definition is locked to that toolkit date.
Expanded exceptions for payments, preserved broad liability safe harbors, and new sponsor payment flows could increase opportunities for improper inducements or fraud and make enforcement harder for regulators.
The bill authorizes open-ended federal spending for outreach, payments, devices, and program implementation and also reduces modest tax revenue, which could increase costs to taxpayers or pressures on other federal priorities.